The Rebirth of Matrix Metalloproteinase Inhibitors: Moving Beyond the Dogma
The pursuit of matrix metalloproteinase (MMP) inhibitors began in earnest over three decades ago. Initial clinical trials were disappointing, resulting in a negative view of MMPs as therapeutic targets. As a better understanding of MMP biology and inhibitor pharmacokinetic properties emerged, it bec...
| Hlavní autor: | |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
MDPI AG
2019-08-01
|
| Edice: | Cells |
| Témata: | |
| On-line přístup: | https://www.mdpi.com/2073-4409/8/9/984 |